Journal
JOURNAL OF DERMATOLOGY
Volume 49, Issue 5, Pages 560-563Publisher
WILEY
DOI: 10.1111/1346-8138.16326
Keywords
de novo onset; deterioration; immunoglobulin A nephropathy; immunoglobulin A vasculitis; severe acute respiratory syndrome coronavirus 2 vaccination
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology [24390276]
- Ministry of Health, Labor, and Welfare
- Ministry of Education, Culture, Sports, Science, and Technology
- Grants-in-Aid for Scientific Research [24390276] Funding Source: KAKEN
Ask authors/readers for more resources
SARS-CoV-2 vaccination may trigger or worsen IgA vasculitis, particularly in female patients.
Immunoglobulin (Ig)A vasculitis/nephropathy is a systemic immune complex-mediated vasculitis. Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is widely recommended in individuals without specific allergy to the vaccine components, it is arguable whether vaccination is advisable for patients with IgA vasculitis or for predisposed individuals. We and others have presented cases of IgA vasculitis occurring after SARS-CoV-2 vaccination. In total, these 19 cases, including ours, involved predominantly female patients, and half of them were suffering from de novo vasculitis onset. The most frequent manifestation was gross hematuria (89.5%) while skin lesions were relatively infrequent, occurring in only five cases (26.3%), of which three (15.8%) were confirmed to be IgA vasculitis. Taken together, these cases suggest that SARS-CoV-2 vaccination might be a trigger for development/deterioration of IgA vasculitis/nephropathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available